Agency Will Request More Voluntary Safety Data Disclosure By Sponsors
This article was originally published in The Pink Sheet Daily
Executive Summary
Controversy involving pediatric antidepressant use has encouraged FDA to accelerate public release of safety review data, Acting Deputy Commissioner for Policy Sachdev says. A planned partnership with CMS will also allow for better post-marketing safety surveillance.
You may also be interested in...
Pediatric Exclusivity Studies Will Be Included In Labeling, FDA Says
FDA is in the process of developing a policy for including results from studies conducted under the Best Pharmaceuticals for Children Act in labeling, Office of Medical Policy Director Temple says during House hearing on antidepressants.
FDA/CMS Formal Collaboration Will Include Data Sharing, Parallel Review
A draft memorandum of understanding is under review at both agencies, Centers for Medicare & Medicaid Services Chief Medical Officer Sean Tunis, MD, told the BIO annual meeting in San Francisco. The MOU will address parallel review for new technologies, and allow the agencies to share scientific expertise and data.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability